ArticleAbdominal radiology (New York)2025
Recurrence risk prediction for non-muscle-invasive bladder urothelial carcinoma using diffusion and clinicopathology features.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the prognostic value of apparent diffusion coefficient (ADC) metrics, MRI characteristics, and clinicopathological parameters in predicting non-muscle-invasive bladder urothelial carcinoma (UCB) recurrence, and to develop a novel multiparametric risk stratification framework.
methodsThis retrospective single-center study (n = 135) with histologically confirmed non-muscle-invasive UCB diagnosed between January 2015 and March 2023. ADC values, vesical imaging reporting and data system (VI-RADS) scores, and clinicopathological variables were analyzed with recurrence-free survival (RFS) as the primary endpoint. Prognostic determinants were identified using univariate and multivariate Cox proportional hazard regression models. An advanced risk stratification system was developed using independent predictors and validated against the European Association of Urology (EAU) risk classification using concordance index (C-index).
resultsMultivariate analysis identified three independent predictors: ADC values (HR = 0.104, 95% confidence interval (CI) 0.025-0.436), hemoglobin levels (HR = 0.463, 95% CI 0.223-0.960), and pathological grade (HR = 2.079, 95% CI 1.098-3.936). The combined model incorporating these parameters demonstrated moderate predictive accuracy (C-index = 0.724, 95% CI 0.655-0.794). Notably, VI-RADS scores showed no independent prognostic value. Risk stratification based on ADC (≤ 1343.22 × 10⁻⁶ mm²/s), hemoglobin (< 113.2 g/L), and pathological grade demonstrated superior discriminative capacity compared to EAU criteria (C-index: 0.667 vs. 0.605).
conclusionA multidimensional prognostic framework integrating quantitative ADC metrics, hemoglobin levels, and pathological grading significantly outperforms conventional EAU stratification in predicting non-muscle-invasive UCB recurrence, providing clinically actionable thresholds for personalized risk stratification and UCB management.
Indexed as
Identifiers
40434425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.